



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: January 7, 2011

To: NCCTG Primary Clinical Research Associates

From: Jack Beranek
Research Protocol Specialist

Re: N0572, A Phase I/II Trial of Sorafenib and CCI-779 in Patients with
Recurrent Glioblastoma

Another addendum (Addendum 18) is in progress due to a change in the CCI-779 labeling. The study team felt it is necessary to distribute Addendum 17 and Update 5 immediately due to the changes in the specimen collection and shipment procedures.

It is our hope that Addendum 18 will be approved and distributed within the next 2 weeks. Therefore, please feel free to hold Addendum 17 and Update 5 until you receive Addendum 18 so that only 1 IRB submission is necessary.

If you have any questions, please feel free to contact me at beranek.john@mayo.edu.